Regenicin, Inc.
RGIN · OTC
9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $3 | $2 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $0 |
| Enterprise Value | $1 | $4 | $2 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$1 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| Net Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.005 | -0.005 | -0.004 | -0.005 |
| % Growth | 6.2% | -17.1% | 19.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |